Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Iovance Biotherapeutics, Inc. Common Stock (IOVA)

Biological Products, (no Disgnostic Substances)

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

825 INDUSTRIAL ROAD, 4TH FLOOR
SAN CARLOS, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/15/2010

Market Cap

3,208,142,980

Shares Outstanding

255,920,000

Weighted SO

255,918,448

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

PTCT --.--%

KRYS --.--%

SRPT --.--%

MDGL --.--%

CVAC --.--%

APLS --.--%

MRTX --.--%

CWBR --.--%

Beta

0.6270

Last Div

0.0000

Range

3.21-18.33

Chg

-0.1000

Avg Vol

7331604

Mkt Cap

3208142980

Exch

NASDAQ

Country

US

Phone

650 260 7120

DCF Diff

10.3872

DCF

0.2064

Div Yield

0.0000

P/S

97.8928

EV Multiple

-7.1392

P/FV

3.9172

Div Yield %

0.0000

P/E

-6.8387

PEG

-0.2992

Payout

0.0000

Current Ratio

5.1502

Quick Ratio

4.8527

Cash Ratio

2.4429

DSO

351.9913

DIO

150.1730

Op Cycle

502.1643

DPO

110.0715

CCC

392.0928

Gross Margin

-1.0658

Op Margin

-14.0136

Pretax Margin

-13.6117

Net Margin

-13.4327

Eff Tax Rate

0.0132

ROA

-0.4565

ROE

-0.6504

ROCE

-0.5275

NI/EBT

0.9868

EBT/EBIT

0.9713

EBIT/Rev

-14.0136

Debt Ratio

0.0129

D/E

0.0162

LT Debt/Cap

0.0013

Total Debt/Cap

0.0159

Int Coverage

-131.7421

CF/Debt

-31.2609

Equity Multi

1.2547

Rec Turnover

1.0370

Pay Turnover

3.3160

Inv Turnover

2.4305

FA Turnover

0.1820

Asset Turnover

0.0340

OCF/Share

-1.3650

FCF/Share

-1.4061

Cash/Share

1.4487

OCF/Sales

-11.8626

FCF/OCF

1.0301

CF Coverage

-31.2609

ST Coverage

-33.9945

CapEx Coverage

-33.1736

Div&CapEx Cov

-33.1736

P/BV

3.9172

P/B

3.9172

P/S

97.8928

P/E

-6.8387

P/FCF

-8.0107

P/OCF

-7.7439

P/CF

-7.7439

PEG

-0.2992

P/S

97.8928

EV Multiple

-7.1392

P/FV

3.9172

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 24, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 18, 02:14 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. Jun 17, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 14, 12:47 ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA GlobeNewswire Inc. Jun 14, 11:48 IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA) GlobeNewswire Inc. Jun 12, 21:49 SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics GlobeNewswire Inc. Jun 12, 02:38 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. Jun 11, 02:33 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. Jun 10, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Digimarc, Elevance Health, and Iovance and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 08, 12:18 IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 14 Deadline (NASDAQ:IOVA) GlobeNewswire Inc. Jun 05, 02:15 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. Jun 04, 02:46 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. Jun 03, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Compass Diversified, Digimarc, Elevance Health, and Iovance and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 01, 21:41 ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA GlobeNewswire Inc. May 29, 02:37 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. May 28, 02:04 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. May 24, 16:09 ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA GlobeNewswire Inc. May 22, 02:50 IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA GlobeNewswire Inc. May 21, 01:24 FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action The Motley Fool May 21, 01:10 Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?

Revenue Product Segmentation